Researchers from Sunovion Pharmaceuticals Inc. presented early clinical data for SEP-363856, a novel trace amine receptor 1 agonist with serotonin 5-HT1A activity, being developed for the treatment of patients with schizophrenia.

Researchers at the Walter and Eliza Hall Institute for Medical Research in Melbourne, Australia, have used a newly developed single-cell clonal multiomics technique to gain a better understanding of the genetic programming underlying how stem cells differentiate into particular cell types.

Chinese neuroscientists have identified a bone marrow (BM) response to acute brain injury, in which the fate and function of BM hematopoietic cells are shaped by brain injury, suggesting that the brain can mobilize a population of protective monocytes and direct them to the injury site.

Organoids cultured from patient-derived colorectal cancer cells have been used to demonstrate for the first time that tumors which have developed resistance to the full range of existing treatments, across chemotherapies, targeted therapies and immunotherapies, retain a requirement for Werner helicase (WRN) for survival. WRN has a key role in the maintenance of genome stability, but although loss of WRN is known to initiate synthetic lethality in DNA mismatch repair deficient colorectal cancer, studies into the effect of inhibiting that helicase have to date been limited to a handful of cell lines.

Australian researchers have discovered a key differentiation process that provides an essential immune function in helping to control cancer and infectious diseases.

DUBLIN – A newly published retrospective analysis of the electronic health care records of more than 500,000 COVID-19 patients has found that infection with SARS-CoV-2 carries “a significantly and substantially” greater risk of cerebral venous thrombosis (CVT) than does either one of the two approved mRNA COVID-19 vaccines or infection with influenza virus.